(NASDAQ: MRKR) Marker Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.57%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.92%.
Marker Therapeutics's earnings in 2025 is -$14,298,034.On average, 5 Wall Street analysts forecast MRKR's earnings for 2025 to be -$15,986,194, with the lowest MRKR earnings forecast at -$15,686,078, and the highest MRKR earnings forecast at -$16,106,241. On average, 4 Wall Street analysts forecast MRKR's earnings for 2026 to be -$28,486,037, with the lowest MRKR earnings forecast at -$44,770,681, and the highest MRKR earnings forecast at -$10,679,138.
In 2027, MRKR is forecast to generate -$18,452,150 in earnings, with the lowest earnings forecast at -$32,352,536 and the highest earnings forecast at -$3,326,289.